Skip to main content

CRISPR treating cancer, Rachel Haurwitz, Co-founder and CEO, Caribou Biosciences

April 15, 2021

“Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems.”

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23, 2021

“AbbVie and Caribou Biosciences, Inc have announced that the companies have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR) T-cell therapeutics.”

AbbVie and Caribou Team Up On Next-Gen Off-the-Shelf CAR-T Therapies

February 18, 2021

“AbbVie and Caribou are partnering to develop next-generation off-the-shelf CAR-T therapies for oncology indications. The collaboration centres around Caribou’s chRDNA technology to overcome challenges facing existing off-the-shelf CAR-T therapies.”

AbbVie, Caribou Biosciences Collaborate in $40 Million CAR-T Cell Deal

February 10, 2021

“AbbVie announced its latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets. AbbVie committed up to another $300 in potential milestone payments.”

CRISPR Technology: Where Female Entrepreneurs Thrive

March 8, 2020

“It wasn’t until Rachel Haurwitz was riding the subway to an attorney’s office in San Francisco to sign papers that she realized the enormousness of what she was doing–cofounding a biotech company.”